89bio Stock

89bio EBIT/Assets

Delisted·Oct 29, 2025

The Operating Income to Assets Ratio (EBIT/Assets) of 89bio (ETNB) as of Aug 16, 2026 is -80.36 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -25.36 % — a change of 216.88% (lower).

EBIT/Assets

-80.36 %

YoY

216.88%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of 89bio is 2026 -80.36 % . Operating Income to Assets Ratio (EBIT/Assets) of 89bio was 2025 -25.36 % . It decreases by 216.88% lower compared to the previous year.
Access this data via the Eulerpool API

89bio Stock analysis

What does 89bio do? 89Bio Inc is an emerging biopharmaceutical company focused on developing drugs to treat metabolic and liver diseases. The company was founded in 2018 and is headquartered in San Francisco, California. 89Bio's business model is based on utilizing innovative science and technology to develop novel and effective therapeutic options for diseases that are currently only limitedly treatable. The company has assembled an interdisciplinary team of scientists, physicians, and entrepreneurs with extensive experience in the pharmaceutical industry. 89Bio has two main divisions: Endocrine and Liver Diseases. In the field of Endocrine Diseases, the company has developed a platform technology based on the binding of human proteins with high affinity and specificity. This technology aims to treat hormone deficiencies in patients with certain endocrine disorders. An example of the application of this technology is 89Bio's leading product, BIO89-100, which is currently in development for the treatment of hypoparathyroidism. The second division of 89Bio is Liver Diseases. The company has developed a pipeline of drug candidates for liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). These diseases are a growing public health concern worldwide as they are associated with obesity, diabetes, and other metabolic disorders. The leading product in this pipeline is BIO89-1000, which aims to improve liver function by activating a specific group of receptors in the body. In recent years, 89Bio has established strong partnerships with leading companies in the pharmaceutical industry to accelerate its research and development. The company has also received funding from renowned global investors to support its growth and expansion. Overall, 89Bio Inc has a promising future as it focuses on developing therapeutic options for serious diseases that are currently inadequately treated. The company has a strong foundation in research and technology, as well as the experience of its leadership team and partnerships. With its new and innovative approaches, 89Bio can make a sustainable contribution to improving healthcare and patient well-being. 89bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 89bio stock

Operating Income to Assets Ratio (EBIT/Assets) of 89bio is -80.36 % in 2026.

Operating Income to Assets Ratio (EBIT/Assets) of 89bio changed from -25.36 % to -80.36 %, representing a 216.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) 89bio since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s 89bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

Profitability — 89bio

All Key Metrics — 89bio